Armata Pharmaceuticals (ARMP) Upgraded by Zacks Investment Research to Hold

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Friday, Zacks.com reports.

According to Zacks, “Armata Pharmaceuticals Inc. is a biotechnology company. It is focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. The company’s principal product candidate consist AP-SA01, targets Staphylococcus aureus including multidrug-resistant strains. It is also developing and advancing a pipeline of synthetic phage candidates, including a synthetic phage for Pseudomonas aeruginosa. Armata Pharmaceuticals Inc., formerly known as AmpliPhi Biosciences Corporation, is based in Marina del Rey, California. “

NYSEAMERICAN ARMP opened at $3.56 on Friday. Armata Pharmaceuticals has a 12-month low of $2.10 and a 12-month high of $19.18.

Armata Pharmaceuticals (NYSEAMERICAN:ARMP) last posted its quarterly earnings results on Monday, May 6th. The company reported ($1.54) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($1.54).

Armata Pharmaceuticals Company Profile

Armata Pharmaceuticals, Inc operates as a clinical-stage biotechnology company focused on the development of bacteriophage therapeutics for antibiotic-resistant infections using its proprietary bacteriophage-based technology. Its product candidate is the AP-SA01 that targets Staphylococcus aureus, including multidrug-resistant strains.

Featured Article: What is an SEC Filing?

Get a free copy of the Zacks research report on Armata Pharmaceuticals (ARMP)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Armata Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Armata Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.